Healthcare of Ontario Pension Plan Trust Fund Sells 28,555 Shares of IDEXX Laboratories, Inc. $IDXX

Posted by Brenda Bartman on Jun 15th, 2026

Healthcare of Ontario Pension Plan Trust Fund decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 22.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 97,610 shares of the company’s stock after selling 28,555 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in IDEXX Laboratories were worth $66,036,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Beacon Investment Advisory Services Inc. grew its stake in IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after purchasing an additional 6,710 shares in the last quarter. Nordea Investment Management AB grew its stake in IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares in the last quarter. NEOS Investment Management LLC grew its stake in IDEXX Laboratories by 82.7% in the third quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after purchasing an additional 13,599 shares in the last quarter. Procyon Advisors LLC bought a new position in IDEXX Laboratories in the fourth quarter worth approximately $1,966,000. Finally, Diversified Trust Co. grew its stake in IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after purchasing an additional 2,901 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $560.88 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The business has a fifty day moving average of $563.06 and a two-hundred day moving average of $626.82. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a market cap of $44.24 billion, a P/E ratio of 41.30, a P/E/G ratio of 3.07 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on IDXX shares. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

Read Our Latest Stock Analysis on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.